Cargando…
To what extent AstraZeneca ChAdOx1 nCoV-19 vaccine is safe and effective? Rapid systematic review
Until now, there are more than two hundred million confirmed cases of COVID-19 including more than seven million deaths. Clinical trials of all three vaccines authorized for use in the UK (Pfizer–BioNTech, Oxford–AstraZeneca, and Moderna) have reported high vaccine efficacy. This rapid systematic re...
Autores principales: | Mohamed Hussein, Aliae A. R., Ibrahim, Islam H., Mahmoud, Islam A., Amary, Marwa, Sayad, Reem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795963/ http://dx.doi.org/10.1186/s43168-021-00109-3 |
Ejemplares similares
-
Acute Arterial Occlusion Following ChAdOx1 nCov-19 (Oxford–AstraZeneca) Vaccination
por: Ali, Azhar, et al.
Publicado: (2022) -
Stevens-Johnson Syndrome Following ChAdOx1 nCoV-19 Vaccination (AstraZeneca)
por: Lee, Hyo Jin, et al.
Publicado: (2023) -
Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination
por: Robichaud, Julie, et al.
Publicado: (2021) -
Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine
por: Clayton-Chubb, Daniel, et al.
Publicado: (2021) -
AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy
por: Ali, Syed B., et al.
Publicado: (2022)